Directory of funded grants

Filter by

551 results found

Teaching Adolescents with type 1 Diabetes Self-compassion (TADS) to reduce diabetes distress: A randomized controlled trial

  • Program Type

    Team grants

  • Area of research

    Mental Health

  • Disease Area

    Other,  Mental illness

  • Competition

    JDRF Canada – Brain Canada Addressing Mental Health in Type 1 Diabetes Team Grants

  • Province

    Ontario

  • Start Date

    2022

  • Total Grant Amount

    $250,000

  • Health Canada Contribution

    $125,000

Project Overview

Self-compassion is a practice that involves acting the same way towards yourself as you would with friends and loved ones, and that you are kind and understanding towards yourself. Since self-compassion is a skill that can be taught, the team believes that it could be a strategy to improve mental…

Project Ongoing

See the project and researchers

TECC-T1D3: Technology-enabled Comprehensive Care for young adults with Type 1 Diabetes and Diabetes Distress

  • Program Type

    Team grants

  • Area of research

    Mental Health

  • Disease Area

    Mental illness,  Other

  • Competition

    JDRF Canada – Brain Canada Addressing Mental Health in Type 1 Diabetes Team Grants

  • Province

    Ontario

  • Start Date

    2022

  • Total Grant Amount

    $250,000

  • Health Canada Contribution

    $125,000

Project Overview

Diabetes distress, the negative emotional feelings resulting from living with diabetes and the burden of selfmanagement, is a very common challenge for people living with type 1 diabetes affecting approximately 40%. It has a major impact on well-being and prevents effective diabetes self-management, increasing the risk of other diabetic complications.…

Project Ongoing

See the project and researchers

Gold and BBB Opening in ALS (The GOALS Trial): A Phase 2a, Open-label, Single-arm Clinical Trial of Oral CNM-Au8 Coupled with Primary Motor Cortex Blood Brain Barrier Opening Using Transcranial MR-guided Focused Ultrasound in Amyotrophic Lateral Sclerosis

  • Program Type

    Team grants

  • Area of research

    Neurodegeneration

  • Disease Area

    ALS

  • Competition

    ALS Canada - Brain Canada Discovery Grants

  • Province

    Ontario

  • Start Date

    2022

  • Total Grant Amount

    $125,000

  • Health Canada Contribution

    $62,500

Project Overview

Rationale: Mitochondrial dysfunction has been identified as a contributing factor for bioenergetic dysregulation and neurodegeneration in the motor cortex and spinal cord of patients with ALS. CNM-Au8 is an investigational compound designed to promote biocatalytic activity and is effective in improving mitochondrial function and survival in preclinical ALS models.  Oral…

Project Ongoing

See the project and researchers

Determination of hypothalamic neuropathology and metabolic defects in ALS

  • Program Type

    Team grants

  • Area of research

    Neurodegeneration

  • Disease Area

    ALS

  • Competition

    ALS Canada - Brain Canada Discovery Grants

  • Province

    Ontario

  • Start Date

    2022

  • Total Grant Amount

    $125,000

  • Health Canada Contribution

    $62,500

Project Overview

Amyotrophic lateral sclerosis (ALS) is a motor neuron disease leading to paralysis and death within 2-5 years from disease onset. Other hallmark features include weight loss and metabolic dysfunction. Several lines of clinical evidence indicated that higher energy expenditure (hypermetabolism) is associated with weight loss in ALS patients. Recent clinical…

Project Ongoing

See the project and researchers

Novel biomarkers of SOD1 pathology in familial and sporadic ALS

  • Program Type

    Team grants

  • Area of research

    Neurodegeneration

  • Disease Area

    ALS

  • Competition

    ALS Canada - Brain Canada Discovery Grants

  • Province

    Québec

  • Start Date

    2022

  • Total Grant Amount

    $125,000

  • Health Canada Contribution

    $62,500

Project Overview

Mutations in the SOD1 gene, leading to the misfolding and toxic aggregation of SOD1 protein, are the second leading cause of Familial Amyotrophic Lateral Sclerosis (FALS-SOD1) and emerging literature has detected misfolded SOD1 (mSOD1) in the cerebrospinal fluid (CSF) and post-mortem tissue of Sporadic ALS (SALS) patients. Based upon the…

Project Ongoing

See the project and researchers